Duvyzat (givinostat) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD) for patients aged 6 years and above. It works by inhibiting histone deacetylase (HDAC), becoming the first non-steroidal drug suitable for all types of DMD genetic variants.
Indications of Duvyzat
The indications of Duvyzat are clearly focused on Duchenne muscular dystrophy (DMD), a rare genetic muscle disease that mainly affects male patients. The drug targets histone deacetylase (HDAC) to regulate gene expression, thereby delaying disease progression.
Disease background of DMD
Duchenne muscular dystrophy is an X-linked recessive genetic disease caused by mutations in the dystrophin gene, manifested as progressive muscle atrophy and loss of function. Patients usually develop the disease in childhood, and as the disease progresses, they gradually lose the ability to walk and may be accompanied by cardiac and respiratory complications. The approval of Duvyzat provides new hope for such patients to delay disease progression.
Applicable population and treatment advantages
Duvyzat is suitable for DMD patients aged 6 years and above, covering all types of genetic variants. Its non-steroidal properties make it an important supplement to existing therapies, especially for patients who do not respond well to other treatments. Clinical trials have shown that Duvyzat can significantly improve patients' muscle function and quality of life.
The indications of Duvyzat not only fill the gap in the field of DMD treatment, but also provide patients with a wider range of treatment options. Its unique pharmacological mechanism and wide applicability make it an important tool in the treatment of DMD.
Contraindications of Duvyzat
Although Duvyzat brings hope to DMD patients, there are clear contraindications and restrictions on its use, and it should be used with caution under the guidance of a doctor.
Thrombocytopenia and bleeding risk
Duvyzat may cause thrombocytopenia and increase the risk of bleeding. Patients need to undergo platelet count testing before treatment. If the value is less than 150×10⁹/L, treatment is prohibited. Platelet levels need to be monitored regularly during treatment, and if abnormalities are found, the dose should be adjusted or the drug should be discontinued in a timely manner.
Heart disease and QT interval prolongation
Patients with congenital long QT syndrome or heart disease should avoid using Duvyzat. The drug may prolong the QT interval and increase the risk of arrhythmia. Closely monitor the electrocardiogram during treatment and avoid co-administration with other drugs that prolong the QT interval.
Duvyzat's contraindications remind us that its use must be strictly followed by medical evaluation and monitoring. For patients with specific risk factors, the pros and cons should be weighed before deciding whether to use the drug.
Dietary structure of patients taking Duvyzat
During Duvyzat treatment, the patient's dietary structure has an important impact on the efficacy and safety of the drug. Reasonable dietary arrangements can reduce adverse reactions and improve the therapeutic effect.
Effect of high-fat diet
When Duvyzat is taken with a high-fat meal, drug exposure may increase by 40%. Patients should avoid long-term high-fat diets to maintain stable blood drug concentrations. Blood lipid levels need to be monitored regularly during treatment. If triglycerides exceed 300 mg/dL, diet or drug dosage needs to be adjusted.
Importance of balanced nutrition
DMD patients are often accompanied by malnutrition and metabolic abnormalities. During treatment, a balanced intake of protein, vitamins and minerals should be confirmed to support muscle health and overall metabolism. If necessary, you can consult a nutritionist to develop a personalized diet plan.
A reasonable diet structure is an important aid to the success of Duvyzat treatment. By scientifically arranging a diet, patients can better control adverse drug reactions and improve their overall health.
